<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128995</url>
  </required_header>
  <id_info>
    <org_study_id>R01DK119450</org_study_id>
    <nct_id>NCT04128995</nct_id>
  </id_info>
  <brief_title>Surgical or Medical Treatment</brief_title>
  <acronym>ST2OMP</acronym>
  <official_title>Surgical or Medical Treatment for Pediatric Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that metabolic bariatric surgery will be more effective&#xD;
      at providing durable glycemic control and reduce co-morbidities than intensive medical&#xD;
      therapy in youth with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Youth-onset type 2 diabetes (T2D) leads to early dependence on exogenous insulin and&#xD;
      progression of T2D co-morbidities, including dyslipidemia, hypertension, non-alcoholic fatty&#xD;
      liver disease and diabetic kidney disease. The pathophysiology of T2D in youth differs&#xD;
      considerably from adults and current treatment approaches are in-adequate for youth. Thus,&#xD;
      exploration of innovative approaches to reduce co-morbidities is critical. Metabolic&#xD;
      bariatric surgery (MBS) significantly improves multiple outcomes in adults with T2D. Initial&#xD;
      small, uncontrolled studies of Roux-en-Y gastric bypass also suggest beneficial effects in&#xD;
      youth with T2D, but definitive studies and understanding of mechanisms in youth-onset T2D are&#xD;
      lacking, especially with the now more common form of MBS, vertical sleeve gastrectomy (VSG).&#xD;
&#xD;
      We will test the hypothesis that VSG will be more effective in reducing glycemia and&#xD;
      comorbidities than the best currently available medical treatment: advanced medical therapy&#xD;
      (AMT), via pancreatic, enterohepatic and/or metabolic changes. To test this hypothesis, 90&#xD;
      adolescents with T2D will be studied to compare the effects of VSG vs. AMT on glycemic&#xD;
      control and T2D-associated comorbidities, as well as underlying mechanisms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 5, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label prospective clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic Control</measure>
    <time_frame>At one year</time_frame>
    <description>Hemoglobin A1c of &lt;6.5%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic Control</measure>
    <time_frame>At two years</time_frame>
    <description>Hemoglobin A1c &lt;6.5% at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Variability</measure>
    <time_frame>At one year</time_frame>
    <description>Time In Range by Continuous Glucose Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta Cell Function</measure>
    <time_frame>at 1 and 2 years</time_frame>
    <description>Oral disposition index= Insulin secretion [insulinogenic index] * insulin sensitivity [1/fasting insulin]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha cell function</measure>
    <time_frame>at 1 and 2 years</time_frame>
    <description>Glucagon area under the curve from mixed meal tolerance testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incretin Response</measure>
    <time_frame>at 1 and 2 years</time_frame>
    <description>GLP-1 area under the curve from mixed meal tolerance testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty Liver Disease</measure>
    <time_frame>at 1 and 2 years</time_frame>
    <description>Hepatic Fat (&lt;5% )by Magnetic Resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyslipidemia</measure>
    <time_frame>at 1 and 2 years</time_frame>
    <description>LDL &lt;130mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>at 1 and 2 years</time_frame>
    <description>Blood pressure &lt;130/80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic Kidney Disease</measure>
    <time_frame>At 1 and 2 years</time_frame>
    <description>Urinary albumin excretion &lt;30Î¼g/mg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Pediatric Obesity</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <arm_group>
    <arm_group_label>Bariatric Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric Surgery</intervention_name>
    <description>Vertical Sleeve Gastrectomy and Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin</description>
    <arm_group_label>Bariatric Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advanced Medical Therapy</intervention_name>
    <description>Use of combination medical therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin</description>
    <arm_group_label>Medical Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 13-19.9 years of age at time of consent&#xD;
&#xD;
          -  Type 2 diabetes by the American Diabetes Association criteria&#xD;
&#xD;
          -  Negative diabetes-associated antibodies&#xD;
&#xD;
          -  BMI greater than or equal to 35&#xD;
&#xD;
          -  Willingness to take oral medications and/or diabetes subcutaneous medications as&#xD;
             medically indicated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known type 1 diabetes of maturity onset diabetes on the young (MODY) or secondary&#xD;
             diabetes&#xD;
&#xD;
          -  Chronic kidney or liver disease (except NAFLD or DKD)&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Genetic cause of obesity or hypothalamic obesity&#xD;
&#xD;
          -  Prior bariatric surgery&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Current participating in another clinical trial affecting study outcomes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy S Shah, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Childrens Hospital Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristen J Nadeau, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Colorado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael A Helmrath, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas H Inge, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Colorado</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy S Shah, MD</last_name>
    <phone>513-636-4744</phone>
    <email>amy.shah@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristen J Nadeau, MD</last_name>
    <phone>(720) 777-6128</phone>
    <email>Kristen.Nadeau@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Baumgartner</last_name>
      <phone>720-777-6143</phone>
      <email>amy.baumgartner@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Kristen J Nadeau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas H Inge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Megan M Kelsey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenni Sizemore</last_name>
      <phone>513-636-4744</phone>
      <email>jenni.sizemore@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Michael A Helmrath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy S Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stavra Xanthakos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Medical Center, Cincinnati</investigator_affiliation>
    <investigator_full_name>Amy Shah</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The PI's will also report a of summary results information (including adverse events) after completion of the study. All data from the study including any negative findings will be published in peer reviewed manuscripts.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

